Pagaduan Jayson V, Ali Mahesheema, Dowlin Michael, Suo Liye, Ward Tabitha, Ruiz Fadel, Devaraj Sridevi
Department of Pathology & Immunology, Baylor College of Medicine, Department of Pathology and Immunology, Texas Children's Hospital, Houston, TX 77030, USA.
Pract Lab Med. 2018 Jan 3;10:34-37. doi: 10.1016/j.plabm.2018.01.001. eCollection 2018 Mar.
Recent sweat chloride guidelines published by the Cystic Fibrosis Foundation changed the intermediate sweat chloride concentration range from 40-59 mmol/L to 30-59 mmol/L for age > 6 months. We wanted to know how this new guideline would impact detection of cystic fibrosis among patients who previously had sweat tests done at Texas Children's Hospital.
We revisited sweat chloride test results (n = 3012) in the last 5 years at Texas Children's Hospital based on the new guidelines on diagnosis of cystic fibrosis from the Cystic Fibrosis Foundation.
We identified 125 patients that would be reclassified in the intermediate sweat chloride value with the new guidelines that were classified as "unlikely to have CF" in the previous guidelines. 8 (32%) patients with CFTR gene testing were positive for CFTR gene mutation(s). 4 (50%) of these patients were identified to have 2 CFTR mutations. One had variant combination that was reported to cause CF but all were diagnosed with CFTR-related metabolic syndrome.
Our findings concur with the new CF diagnosis guidelines that changing the intermediate cut-off to 30-59 mmol/L sweat chloride concentration in combination with CFTR genetic analysis enhances the probability of identifying individuals that have risk of developing CF or have CF and enables for earlier therapeutic intervention.
囊性纤维化基金会发布的最新汗液氯化物指南将6个月以上儿童的中间汗液氯化物浓度范围从40 - 59 mmol/L改为30 - 59 mmol/L。我们想了解这一新指南将如何影响之前在德克萨斯儿童医院进行汗液检测的患者中囊性纤维化的检测。
根据囊性纤维化基金会关于囊性纤维化诊断的新指南,我们回顾了德克萨斯儿童医院过去5年的汗液氯化物检测结果(n = 3012)。
我们发现125例患者根据新指南汗液氯化物值将被重新分类为中间值,而在之前的指南中被归类为“不太可能患有CF”。8例(32%)进行CFTR基因检测的患者CFTR基因突变呈阳性。其中4例(50%)患者被确定有2种CFTR突变。1例具有据报道可导致CF的变异组合,但所有患者均被诊断为CFTR相关代谢综合征。
我们的研究结果与新的CF诊断指南一致,即将中间临界值改为汗液氯化物浓度30 - 59 mmol/L并结合CFTR基因分析可提高识别有患CF风险或患有CF的个体的概率,并能实现更早的治疗干预。